IMC Chicago
CRSP icon

IMC Chicago’s CRISPR Therapeutics CRSP Stock Holding History

IMC Chicago’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Sell
305,800
-9,100
-3% -$480K ﹤0.01% 1186
2026
Q1 		$15M Sell
314,900
-165,000
-34% -$8.7M 0.01% 1007
2025
Q4 		$25.2M Buy
479,900
+84,300
+21% +$5.05M 0.01% 745
2025
Q3 		$25.6M Sell
395,600
-120,600
-23% -$6.92M 0.01% 681
2025
Q2 		$25.1M Buy
516,200
+281,800
+120% +$10.9M 0.01% 606
2025
Q1 		$7.98M Buy
234,400
+6,000
+3% +$254K ﹤0.01% 983
2024
Q4 		$8.99M Buy
228,400
+95,400
+72% +$4.5M ﹤0.01% 952
2024
Q3 		$6.25M Sell
133,000
-16,100
-11% -$817K ﹤0.01% 1035
2024
Q2 		$8.05M Buy
149,100
+57,100
+62% +$3.3M ﹤0.01% 864
2024
Q1 		$6.27M Sell
92,000
-98,100
-52% -$7.02M ﹤0.01% 887
2023
Q4 		$11.9M Buy
190,100
+32,700
+21% +$1.81M 0.01% 599
2023
Q3 		$7.14M Sell
157,400
-10,200
-6% -$527K 0.01% 650
2023
Q2 		$9.41M Sell
167,600
-19,200
-10% -$1.09M 0.01% 523
2023
Q1 		$8.45M Buy
186,800
+20,400
+12% +$991K 0.01% 529
2022
Q4 		$6.76M Sell
166,400
-14,300
-8% -$759K 0.01% 542
2022
Q3 		$11.8M Sell
180,700
-28,800
-14% -$2.09M 0.02% 409
2022
Q2 		$12.7M Buy
209,500
+87,200
+71% +$5.13M 0.02% 381
2022
Q1 		$7.68M Buy
122,300
+15,600
+15% +$980K 0.01% 507
2021
Q4 		$8.09M Buy
106,700
+5,200
+5% +$454K 0.01% 523
2021
Q3 		$11.4M Buy
101,500
+2,200
+2% +$276K 0.01% 468
2021
Q2 		$16.1M Buy
99,300
+1,300
+1% +$158K 0.02% 378
2021
Q1 		$11.9M Buy
+98,000
New +$14.8M 0.02% 402

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IMC Chicago's CRSP Position: Q2 2026 in Review

IMC Chicago opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10,709 shares worth $584K. The stake represents ﹤0.01% of the portfolio and ranks #4463 among its holdings. This is a return to the name: IMC Chicago previously reported a position in CRSP as recently as Q2 2025.

IMC Chicago first reported a position in CRSP in Q1 2021 and has held it in 15 quarters since. The position peaked at $3.49M in Q4 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • IMC Chicago held 10,709 shares of CRISPR Therapeutics worth $584K as of Q2 2026.
  • CRISPR Therapeutics was a new IMC Chicago position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4463 holding.
  • IMC Chicago first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • IMC Chicago's CRISPR Therapeutics position peaked at $3.49M in Q4 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.